W. Nicholas Haining, BM, BCh, is chief scientific officer and co-founder of ArsenalBio. He is a physician-scientist, and prior to co-founding ArsenalBio, he was the vice president of discovery oncology and immunology at Merck Research Laboratories. Dr. Haining received his undergraduate and medical degree from Oxford University and completed his medical training in pediatrics at Boston Children’s Hospital, and subsequently in pediatric hematology/oncology at Dana-Farber Cancer Institute. As an associate professor of pediatrics at Harvard Medical School and an associate member of the Broad Institute of MIT and Harvard, his lab defined some of the key transcriptional and epigenetic regulators of T cell exhaustion and used in vivo genetic screens to identify immune vulnerabilities of cancer cells in mouse models. He also led a multi-disciplinary organization at Merck that focused on using innovative approaches to identify new therapeutic strategies for cancer and immunological disease.